Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
01 3Aprovel
02 5Cozaar/Hyzaar
03 1Diovan
04 5Diovan Group
05 2Diovan/Co-Diovan
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2019 Revenue in Millions : 735
2018 Revenue in Millions : 711
Growth (%) : 3
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 670
2019 Revenue in Millions : 815
Growth (%) : -18
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 461
2020 Revenue in Millions : 604
Growth (%) : -24
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 386
2019 Revenue in Millions : 442
Growth (%) : -13
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 1,003
2019 Revenue in Millions : 1,064
Growth (%) : -6
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 357
2020 Revenue in Millions : 386
Growth (%) : -8
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 773
2020 Revenue in Millions : 1,003
Growth (%) : -23
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 323
2021 Revenue in Millions : 357
Growth (%) : -10
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 652
2021 Revenue in Millions : 773
Growth (%) : -16
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 281
2022 Revenue in Millions : 323
Growth (%) : -13
LOOKING FOR A SUPPLIER?